Thus, the three major goals of future biomarker studies, as discussed in our review, should be the following: (1) to differentiate types of AKI at the time of diagnosis (acute tubular necrosis vs. prerenal vs. other); (2) to predict or diagnose AKI earlier than the 'delayed' clinical diagnosis via creatinine; (3) to predict hard outcomes (need for dialysis, length of stay, death) at the time of injury.
In the absence of associations between biomarkers and these hard end points, the availability of another biomarker that 'mimics' creatinine will not be beneficial in advancing the field of AKI. We would encourage Ferrannini et al. to perform the analyses we have mentioned in order to determine how cystatin C performs for predicting these types of end points. To the Editor: The article by Davenport et al. 1 suggests that improved blood pressure control increases intradialytic hypotension. It is unlikely that the reported higher incidence of hypotension is caused by trying to achieve the Renal Association targets alone.
In a study of 991 dialysis treatments in 111 patients over a 3-week period, we documented predialysis blood pressures of 136.9 ± 23.4/67.8 ± 14.0 mm Hg and postdialysis blood pressures of 133.0 ± 24.0/65.8 ± 12.5 mm Hg. The Renal Association targets were achieved by 56.8% of patients predialysis, 44.1% postdialysis, and 37.8% achieved both targets. Intradialytic hypotension occurred in 2.4% of all treatments. No significant differences were demonstrated in the blood pressure, interdialytic weight gains or prescribed medication of those who experienced hypotension and those who did not.
Two critical factors implemented in our unit may contribute to these findings. We recognize that short dialysis times make ultrafiltration more difficult to tolerate and increase the potential for hypotension. Longer treatment times are utilized whenever possible with the modal dialysis time being 4.5 h. Our center utilizes postdilution hemodiafiltration as standard. There is increasing evidence that the use of hemodiafiltration is associated with improvements in blood pressure control, incidence of intradialytic hypotension and a reduction in mortality. [2] [3] [4] Predialysis hypertension does not obviate hypotension episodes 5 and not having targets for blood pressure control will not necessarily reduce the frequency of hypotension episodes. When improved control of blood pressure is desired, modifications to the dialysis treatment itself should be considered as part of the management strategy.
